Liposomal drug delivery

Journal of Infusion Nursing

Volumn 30, Issue 2, 2007, Pages 89-95

  Allison, S Dean ^a,b  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Department of Clinical Pharmacy and Outcomes Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CHOLESTEROL; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; LIPOSOME; MORPHINE SULFATE; NYSTATIN; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID; STEALTH; UNCLASSIFIED DRUG;

ALOPECIA; AQUEOUS SOLUTION; BILAYER MEMBRANE; BIOAVAILABILITY; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FEVER; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG TARGETING; DRUG UPTAKE; ENCAPSULATION; HAND FOOT SYNDROME; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; INFLAMMATION; LIPID VESICLE; LOW DRUG DOSE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TISSUE DISTRIBUTION; TUMOR; VOMITING;

AMPHOTERICIN B; DOXORUBICIN; DRUG DELIVERY SYSTEMS; EDUCATION, CONTINUING; LIPOSOMES;

EID: 34147194589     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.NAN.0000264712.26219.67     Document Type: Review

References (27)

1. Abraham SA, Waterhouse DN, Mayer LD, et al. The liposomal formulation of doxorubicin. Meth Enzymol. 2005;391:71-97.
2. Forssen EA, Tokes ZA. In vitro and in vivo studies with adriamycin liposomes. Biochem Biophys Res Comm. 1979;91:1295-1301.
3. Vanrenswoude J, Hoekstra D. Cell-induced leakage of liposome contents. Biochem. 1981;20(3):540-546.
4. Margolis LB, Victorov AV, Bergelson LD. Lipid-cell interactions: a novel mechanism of transfer of liposome-entrapped substances into cells. Biochim Biophys Acta. 1982;720(3):259-265.
5. Miller DC, Dahl GP. Early events in calcium-induced liposome fusion. Biochim Biophys Acta. 1982;689(1):165-169.
6. Andresen TL, Jensen SS, Jorgensen K. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res. 2005;44(1):68-97.
7. Yatvin MB, Weinstein JN, Dennis WH, et al. Design of liposomes for enhanced local release of drugs by hyperthermia. Science. 1978;202(4374):1290-1293.
8. Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta. 1991;1068(2):133-141.
9. Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A. 1991;88:11460-11464.
10. Needham D. Temperature-Sensitive Liposome Formulation. Durham, NC: Duke University.
11. Mamot C, Drummond DC, Greiser U, et al. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFR-vIII-overexpressing tumor cells. Cancer Res. 2003;63(12):3154-3161.
12. Chow CY, Heath TD. Rapid diffusion of the lipid phosphorus of phosphatidyl glycerol liposomes through polycarbonate membranes is caused by the oxidation of the unsaturated fatty-acids. Biochim Biophys Acta. 1995;1239(2):168-176.
13. Gordon SG, Phillipo F, Borgen KS, et al. Formation of fatty acid ethyl esters during lipid extraction and storage-an important artifact. Biochim Biophys Acta. 1970;218(2):366-368.
14. Cowers JW, Creaven PJ, Creco WB, et al. Initial clinical (phase I) trial of TLC-D99 (doxorubicin encapsulated in liposomes). Cancer Res. 1993;53:2796-2802.
15. Bradley AJ, Devine DV, Ansell SM, et al. Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol) lipids. Arch Biochem Biophys.1998;357(2):185-194.
16. Gabizon A, Catime R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene glycol-coated liposomes. Cancer Res. 1994;54:987-992.
17. Tardi PG, Barnam NL, Cullis PR. Liposomal doxorubicin. J Drug Target. 1996;4:129-140.
18. Pharmacia. Adriamycin (doxorubicin hydrochloride): US full prescribing information. Kalamazoo, MI: Pharmacia; 2000. Available at: http:/www.pharmacia. com/products/pharm.asp. Accessed August 2006.
19. Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002;94:25-36.
20. O'Brien MER, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil® ) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440-449.
21. Waterhouse DN, Tardi PG, Mayer LD, et al. A comparison of liposomal formulations of doxorubicin with drugs administered in free form: changing toxicity profiles. Drug Safety. 2001;24:903-916.
22. Andes D, Safdar N, Marchillo K, et al. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother. 2006;50:674-684.
23. Alexander BD, Wingard JR. Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis. 2005;40 (Suppl. 6):S414-421.
24. Janoff AS, Penting WR, Saleton SL, et al. Amphotericin B lipid complex: a molecular rationale for the attenuation of amphotericin B-related toxicities. J Liposome Res. 1993;3:451-472.
25. Subria M, Martino R, Gomez L, et al. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies: a randomized, controlled trial. Eur J Haematol. 2004;72:342-347.
26. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med. 1999;340:764-771.
27. Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis. 2000;31:1155-1163.